[ad_1] AGOURA HILLS, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We” or “Our”), announced today its Chief Executive Officer (“CEO”), Dr. Vuong…
Tag: Therapeutics
Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023
[ad_1] Geneva, Switzerland, November 23, 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that that it will…
Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business
[ad_1] Altamira Therapeutics Ltd Initiates Strategic Repositioning to Focus on Company’s Core RNA Delivery Technology Altamira Therapeutics retains 49% in Altamira Medica AG, and secures 25% of future licensing revenue…
CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update
[ad_1] Conference call webcast is scheduled for November 22 at 9 a.m. ET. SINGAPORE, Nov. 17, 2023 /PRNewswire/ — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company…
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights | BioSpace
[ad_1] WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients…
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
[ad_1] SAN DIEGO, Calif. and ZUG, Switzerland, Nov. 10, 2023 /PRNewswire/ — Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that following a re-examination procedure, the…
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
[ad_1] Marker Therapeutics Announced complete response in first patient with lymphoma treated with MT-601 in Phase 1 APOLLO trial following CAR T relapse Received Orphan Drug Designation (ODD) from European…
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
[ad_1] Enrollment Continues in Phase 2a Clinical Study of RG6501 (OpRegen®) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) Under Management of Genentech, a Member of…
Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
[ad_1] Presented updated data from Phase 1 clinical trial of CT-0508 at CAR-TCR Summit, further supporting CAR-M safety, feasibility and mechanism of action Selected clinical candidate for CT-1119, an anti-mesothelin…
Neogap Therapeutics from Sweden receives €7.1M funding boost for personalized cancer treatment research – ArcticStartup
[ad_1] – Advertisement – Neogap Therapeutics, a Stockholm-headquartered biotech company, has secured €7.1 million (SEK 83 million) for its clinical phase I/II cancer study, with €4.64 million (54MSEK) from a…